Caris Life Sciences (NASDAQ:CAI) Insider Luke Thomas Power Sells 62,250 Shares

Caris Life Sciences, Inc. (NASDAQ:CAI) insider Luke Thomas Power sold 62,250 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the completion of the sale, the insider directly owned 99,571 shares in the company, valued at $2,646,597.18. This represents a 38.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Caris Life Sciences Price Performance

Shares of CAI traded up $0.22 during mid-day trading on Friday, reaching $26.76. The company had a trading volume of 1,785,315 shares, compared to its average volume of 2,430,878. Caris Life Sciences, Inc. has a 52 week low of $22.86 and a 52 week high of $42.50.

Analysts Set New Price Targets

CAI has been the topic of a number of analyst reports. Wall Street Zen cut shares of Caris Life Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, December 6th. Weiss Ratings reiterated a “sell (d)” rating on shares of Caris Life Sciences in a research note on Wednesday. Finally, Canaccord Genuity Group started coverage on shares of Caris Life Sciences in a research report on Tuesday, December 2nd. They set a “hold” rating and a $28.00 price target for the company. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $28.00.

About Caris Life Sciences

We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.